Jakafi and Ipratropium bromide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jakafi (ruxolitinib phosphate) and Ipratropium bromide (ipratropium bromide). Common drug interactions include platelet count increased among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Jakafi and Ipratropium bromide. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.

On Jul, 19, 2026

50 people who take Jakafi and Ipratropium bromide together, and have interactions are studied.

Jakafi and Ipratropium bromide drug interactions.

What are the common drug interactions of Jakafi and Ipratropium Bromide, by gender? *:

female:

Platelet count increased
Alopecia (absence of hair from areas of the body)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Hypersensitivity
Malaise (a feeling of general discomfort or uneasiness)
Pneumonia
Viral diarrhoea
Vomiting
Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body)
Cough

male:

Pneumonia
Bone pain
Arthralgia (joint pain)
Asthenia (weakness)
Contusion (a type of hematoma of tissue in which capillaries)
Decreased appetite
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Haemoglobin decreased
Herpes zoster oticus (viral infection of the inner, middle, and external ear caused by varicella-zoster virus (vzv))

What are the common drug interactions of Jakafi and Ipratropium Bromide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Pneumonia
Malaise (a feeling of general discomfort or uneasiness)
Sepsis (a severe blood infection that can lead to organ failure and death)
Arthralgia (joint pain)
Asthenia (weakness)
Contusion (a type of hematoma of tissue in which capillaries)
Decreased appetite
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Haemoglobin decreased

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 16 people, 32.00%
Connective Tissue Disorder (any disease that has the connective tissues of the body): 5 people, 10.00%
High Blood Pressure: 5 people, 10.00%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 4 people, 8.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 8.00%
Anaemia (lack of blood): 3 people, 6.00%
Antiphospholipid Syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss): 3 people, 6.00%
Constipation: 3 people, 6.00%
Depression: 3 people, 6.00%
Gastric Ulcer (stomach ulcer): 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and Ipratropium bromide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously